{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.9","upperLimit":"23.5","value":"16.1"},{"groupId":"OG001","lowerLimit":"5.9","upperLimit":"13.1","value":"11.2"},{"groupId":"OG002","lowerLimit":"1.3","upperLimit":"19.4","value":"10.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"description":"Overall survival is defined as the duration from initiation of ruxolitinib treatment to the date of death from any cause.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Cohort 1) 5mg ruxolitinib\n\nCarfilzomib: Irreversible proteasome inhibitor\n\nRuxolitinib: Oral JAK inhibitor\n\nDexamethasone: glucocorticoid","id":"OG000","title":"Phase I 5mg Ruxolitinib"},{"description":"Cohort 2) 10mg ruxolitinib\n\nCarfilzomib: Irreversible proteasome inhibitor\n\nRuxolitinib: Oral JAK inhibitor\n\nDexamethasone: glucocorticoid","id":"OG001","title":"Phase I 10mg Ruxolitinib"},{"description":"Cohort 3) 15mg ruxolitinib\n\nCarfilzomib: Irreversible proteasome inhibitor\n\nRuxolitinib: Oral JAK inhibitor\n\nDexamethasone: glucocorticoid","id":"OG002","title":"Phase I 15mg Ruxolitinib"}],"paramType":"MEDIAN","populationDescription":"All participants who initiate study treatment.","reportingStatus":"POSTED","timeFrame":"approx. 5 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}